On July 29, AstraZeneca announced its H1 2025 performance, with total revenue of $28.045 billion (+11%) in the first half of the year, including product revenue of $27.963 billion.Billion USD (+11%); R&D investment of USD billion, a year-on-year increase of %.In terms of regional distribution, the U.S. market revenue reached $11.97 billion in the first half of 2025 (+12%), Emerging Markets revenue was $7.697 billion (+12%), with China revenue at $3.515 billion (+5%),Accounting for 13% of AstraZeneca's global market share。AstraZeneca divides its business into oncology,CVRM (Cardiovascular, Renal, and Metabolic Diseases),Respiratory & Immunology (R&I),Vaccines and Immunotherapies (V&I)AndRare Diseases,Five major segments, these segments contributed 119.54 respectivelyBillion USD (+16%), 65.12Billion US dollars（+7%）、42.34Billion US dollars（+13%）、4.11Billion US dollars（+18%）、43.36Billion US dollars（+3%）Income, of whichOncology drugs are AstraZeneca's largest business segment, accounting for 43% of the company's total product revenue.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
In the field of oncology, AstraZeneca's flagship productTagrisso (Osimertinib)MaintainingSteady growth, with revenue of $3.488 billion (+10%) in the first six months. In the first half of the year, the productComprehensively covering Stage III NSCLC in China, the United States, Europe, and Japan,And inApproved in China this June for second-line treatment in combination with Savolitinib for NSCLC patients with MET amplification, becoming the first all-oral combination treatment regimen for this population. These will provide new momentum for its growth.
In addition, multiple oncology products have shown remarkable performance, especiallyEnhertu (Trastuzumab Deruxtecan) andTruqap（Capivasertib）。Enhertu expanded its eligible population to include HER2 ultra-low expression breast cancer in the U.S. and Europe in January and April this year, respectively, providing a new growth point for its performance.Revenue for the first half of the year: 12.62Billion US dollars（+38%）。If the revenue reported by Daiichi Sankyo is included,Enhertu's sales in the first half of the year were $2.289 billion (+29%)。In addition, AstraZeneca's second ADC productDatroway（Dedabotumab was approved for marketing in the United States this January, and has so far obtained two indications: HR+/HER2- breast cancer and EGFR-mutated NSCLC. Its salesStill in the initial stage, generating $0.14 billion in revenue for AstraZeneca in the first half of the year.Truqap isAnother promising product launched by AstraZeneca in the oncology field since its market debut.Continuous growth, with first-half sales reaching $302 million, already approaching the total sales for 2024 ($430 million). This product is expected to join the "blockbuster" ranks next year.InCVRM Field, in addition to mature productsFarxiga (Dapagliflozin) Shows Strong GrowthIn addition, Lokelma (Sodium Zirconium Cyclosilicate) and Wainua (eplontersen) Two productsNext-generation products are gradually opening up the market. It is worth mentioning that antihypertensive drugs with a novel mechanismBaxdrostat successfully completed Phase III study this month, and is expected to become new blood for AstraZeneca's CVRM business.InRespiratory & Immunology (R&I)) Field，AstraZeneca's multiple products have performed well, such as the triple combination for COPD.Breztri（Budesonide + Glycopyrronium Bromide + Formoterol), asthma drug Tezspire (Tezepelumab), and systemic lupus erythematosus drugSaphnelo（Avelumab）。
InVaccines and Immunotherapies (V&I)) Field, the best-performing product is undoubtedly the RSV neutralizing antibody Beyfortus (Nirsevimab). This product has had strong commercial performance since its launch, and last year itPromoted to "blockbuster." In the first half of this year,Beyfortus Sales Increase More Than Twice Compared to the Same Period, generating $238 million in revenue for AstraZeneca.The first competitor of this product has officially debuted: the neutralizing antibody developed by Merck.Enflonsia（Clesrovimab was approved for marketing by the FDA in June this year.InRare Disease Field, Second-generation C5 monoclonal antibodyUltomiris（Relatlimab) As the successor product, its sales performance was impressive, with a strong sale of $22.28 billion (+24%) in the first half of the year.In 2025, AstraZeneca will reach the regulatory and Phase III study data disclosure milestones as shown in the figure below:Looking ahead to 2025, AstraZeneca expects full-year performance to achieve high single-digit growth.Copyright © 2025 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
